Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned an average recommendation of “Moderate Buy” from the eighteen research firms that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $53.88.

A number of research firms have recently commented on KYMR. UBS Group dropped their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. Stephens started coverage on shares of Kymera Therapeutics in a research note on Monday, November 18th. They issued an “overweight” rating and a $65.00 price objective on the stock. Guggenheim upped their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Oppenheimer raised their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th.

Kymera Therapeutics Stock Down 4.5 %

Shares of Kymera Therapeutics stock opened at $40.11 on Friday. Kymera Therapeutics has a 12-month low of $22.35 and a 12-month high of $53.27. The stock has a market capitalization of $2.60 billion, a P/E ratio of -17.14 and a beta of 2.16. The stock has a 50 day moving average price of $45.44 and a two-hundred day moving average price of $43.47.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s revenue was down 20.9% compared to the same quarter last year. During the same period last year, the business posted ($0.90) EPS. Sell-side analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after acquiring an additional 504 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Kymera Therapeutics by 8.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock worth $534,000 after purchasing an additional 915 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Kymera Therapeutics in the 3rd quarter worth about $61,000. Arizona State Retirement System increased its position in shares of Kymera Therapeutics by 15.6% during the 2nd quarter. Arizona State Retirement System now owns 12,830 shares of the company’s stock worth $383,000 after purchasing an additional 1,730 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in Kymera Therapeutics by 12.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 17,300 shares of the company’s stock valued at $819,000 after purchasing an additional 1,900 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.